2023 Highlights


We announced the completion of our Solid Form Services expansion at our Bend (US) site.  

We also reported strong Full-Year 2022 financial results.


We announced the issuance of a CHF 300 million straight bond.

We expanded our Early Development Services Offering in North America.

We announced the completion of the expansion of our conjugation facility in Visp (CH).


We announced the upgrade of our powder characterization capabilities at our Tampa (US) site.

We completed the clinical and commercial drug product manufacturing line in Visp (CH).

We announced the initiation of our share buyback program of up to CHF 2 billion.


We announced the increase of our straight bond by CHF 150 million.


We announced the issuance of a EUR 500 million straight bond.

We expanded our Cell & Gene offering with the launch of the TheraPEAK® T-VIVO® cell culture medium to accelerate cell therapy development.


We announced the acquisition of Synaffix to strengthen our antibody-drug conjugates offering.  

We signed a ten-year Virtual Power Purchase Agreement (VPPA) that will provide solar energy equal to Lonza’s electricity needs across Switzerland and the European Union.

We announced an agreement with Vertex to build a dedicated manufacturing facility for Type-1 diabetes (T1D) cell therapies.


We announced the launch of the TheraPRO® CHO media system to improve productivity and quality in therapeutic protein manufacture.

We communicated our Half-Year 2023 financial results.


We launched the Nebula® Absorbance Reader for streamlined endotoxin and pyrogen testing.


We announced the upgrade of our MODA-ES® Module for enhanced electronic batch record execution.


We announced the expansion of the collaboration with a major biopharmaceutical partner for the manufacture of antibody-drug conjugates.

We announced a new filling line for commercial supply of antibody-drug conjugates for a dedicated customer.

We announced the expansion of our collaboration with Vaxcyte to include global commercial manufacturing of pneumococcal conjugate vaccines (PCVs).

At our Capital Markets Day 2023, we announced our new Mid-Term Guidance 2024 – 2028 and confirmed our 2023 Outlook.


We published the issuance of a dual-tranche straight bond.

We launched the GS Effex® cell line for the development of therapeutic antibodies with increased potency.